1

Microtubule inhibitors and selective G2/M targeted compound tested in GBM in pre-clinical and therapeutic studies

G2/M inhibitorDevelopment statusReference
Anti-microtubule
7-DeazahypoxanthinePre-clinical46
AD-1Pre-clinical47
CabazitaxelPhase III (did not include GBM)48
ChalconePre-clinical49
CI-980Phase I/II (study was stopped)50
ColcemidPre-clinical51
ColchicinePhase III (did not include GBM)51
Combretastatin A4Pre-clinical52
CP248Pre-clinical53
Cucurbitacin BPre-clinical54
D-24851Phase I (did not include GBM)55,56
DocetaxelPhase II57,58
DTA0100Pre-clinical59
Epothilone BPhase I/II60,61
Epothilone DPhase I (did not include GBM)62
IxabepilonePhase I/II61
JAI-51Pre-clinical63
MebendazolePre-clinical64,65
SagopilonePhase II66
ST-11Pre-clinical67
TTI-237Phase I (did not include GBM)68
VitilevuamidePre-clinical69
PLK1 inhibitors
BI 2536Phase II (did not include GBM)70-73
BI 6727Phase I/II (did not include GBM)71,74
GSK461364Phase I/II (did not include GBM)71,75
GW843682XPre-clinical71
JNJ-10198409Pre-clinical70
CDK inhibitors
AbemaciclibPhase I76,77
CVT-313Pre-clinical78
DinaciclibPre-clinical79
FlavopiridolPhase I (did not include GBM)80-83
JNJ-7706621Pre-clinical84
MK-8776Phase I/II (did not include GBM)85
ON123300Pre-clinical86
PalbociclibPre-clinical77,87-90
PHA-767491Pre-clinical91
RoscovitinePre-clinical92,93
SNS-032Phase I (did not include GBM)94,95
THZ1Pre-clinical96
AURK inhibitors
Alisertib
Phase I/II (did not include GBM)97-100
AZD1152Phase II (did not include GBM)101,102
JNJ-7706621Pre-clinical84,103
SA16Pre-clinical99
VX-680Phase II (did not include GBM)104
VE-465Pre-clinical105
ZM 447439Pre-clinical106
Survivin inhibitors
YM155
Phase II (did not include GBM)260,261
M4NPhase I